Download PDF
Semin Respir Crit Care Med 2013; 34(03): 371-379
DOI: 10.1055/s-0033-1348475
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Mold Infections in Lung Transplant Recipients

Archana Bhaskaran
1   Division of Infectious Diseases and Multi-Organ Transplantation, University Health Network, University of Toronto, Toronto, Ontario, Canada
,
S.M Hosseini-Moghaddam
2   Division of Infectious Diseases, University of Western Ontario, London, Ontario, Canada
,
Coleman Rotstein
1   Division of Infectious Diseases and Multi-Organ Transplantation, University Health Network, University of Toronto, Toronto, Ontario, Canada
,
Shahid Husain
1   Division of Infectious Diseases and Multi-Organ Transplantation, University Health Network, University of Toronto, Toronto, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2013 (online)

    Permissions and Reprints

Abstract

Fungal infections continue to produce morbidity and mortality in lung transplant recipients despite the widespread use of antifungal prophylaxis. There has been a decline in Candida infections but Aspergillus species predominate. Other mold pathogens including Fusarium, Scedosporium, and Zygomycetes also cause infections in lung transplant recipients. Furthermore, the widespread use of antifungal prophylaxis has prompted a delay in onset of Aspergillus infection in lung transplant recipients. Pulmonary parenchymal disease has become the most common manifestation of invasive aspergillosis. Among the risk factors pre- or posttransplant Aspergillus colonization is the most important risk factor reported in several retrospective studies. Recently posttransplant colonization has been implicated in the development of bronchiolitis obliterans syndrome. Other factors that have been reported include preceding cytomegalovirus infections, hypogammaglobulinemia, and single-lung transplantation. The risk factors for other mold infections such as Scedosporium, Fusarium, and Zygomycetes are not well studied. The best antimold prophylaxis strategy and choice of drug remains to be elucidated. Most lung transplant centers use either voriconazole or inhaled amphotericin preparations. However, data have emerged regarding the increased risk of squamous cell cancer in lung transplant recipients on voriconazole prophylaxis. Advances in the diagnosis and treatment of invasive aspergillosis have resulted in a significant decrease in mortality.

Keywords

lung transplantation - mold - prophylaxis - Aspergillus - Scedosporium - Fusarium - mucormycosis
 

  • References

  • 1 Christie JD, Edwards LB, Kucheryavaya AY , et al; International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31 (10) 1073-1086
    CrossrefPubMedGoogle Scholar
  • 2 Husain S. Unique characteristics of fungal infections in lung transplant recipients. Clin Chest Med 2009; 30 (2) 307-313 , vii
    CrossrefPubMedGoogle Scholar
  • 3 Chan KM, Allen SA. Infectious pulmonary complications in lung transplant recipients. Semin Respir Infect 2002; 17 (4) 291-302
    CrossrefPubMedGoogle Scholar
  • 4 Engelmann I, Hesse N, Fegbeutel C , et al. Incidence and impact of herpes simplex and cytomegalovirus detection in the respiratory tract after lung transplantation. Transpl Infect Dis 2011; 13 (3) 259-265
    CrossrefPubMedGoogle Scholar
  • 5 Mattner F, Fischer S, Weissbrodt H , et al. Post-operative nosocomial infections after lung and heart transplantation. J Heart Lung Transplant 2007; 26 (3) 241-249
    CrossrefPubMedGoogle Scholar
  • 6 Solé A, Salavert M. Fungal infections after lung transplantation. Transplant Rev (Orlando) 2008; 22 (2) 89-104
    CrossrefPubMedGoogle Scholar
  • 7 Solé A, Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med 2009; 15 (3) 243-253
    CrossrefPubMedGoogle Scholar
  • 8 Pappas PG, Alexander BD, Andes DR , et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50 (8) 1101-1111
    CrossrefPubMedGoogle Scholar
  • 9 Steinbach WJ, Marr KA, Anaissie EJ , et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012; 65 (5) 453-464
    CrossrefPubMedGoogle Scholar
  • 10 Weigt SS, Elashoff RM, Huang C , et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9 (8) 1903-1911
    CrossrefPubMedGoogle Scholar
  • 11 Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123 (3) 800-808
    CrossrefPubMedGoogle Scholar
  • 12 Nunley DR, Ohori P, Grgurich WF , et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998; 114 (5) 1321-1329
    CrossrefPubMedGoogle Scholar
  • 13 Cahill BC, Hibbs JR, Savik K , et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112 (5) 1160-1164
    CrossrefPubMedGoogle Scholar
  • 14 Tofte N, Jensen C, Tvede M, Andersen CB, Carlsen J, Iversen M. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients. Scand J Infect Dis 2012; 44 (11) 835-841
    CrossrefPubMedGoogle Scholar
  • 15 Husain S, Paterson DL, Studer S , et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6 (12) 3008-3016
    CrossrefPubMedGoogle Scholar
  • 16 Husain S, Kwak EJ, Obman A , et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4 (5) 796-802
    CrossrefPubMedGoogle Scholar
  • 17 Husain S, Paterson DL, Studer SM , et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83 (10) 1330-1336
    CrossrefPubMedGoogle Scholar
  • 18 Neofytos D, Fishman JA, Horn D , et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12 (3) 220-229
    CrossrefPubMedGoogle Scholar
  • 19 Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22 (3) 258-266
    CrossrefPubMedGoogle Scholar
  • 20 Nunley DR, Gal AA, Vega JD, Perlino C, Smith P, Lawrence EC. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest 2002; 122 (4) 1185-1191
    CrossrefPubMedGoogle Scholar
  • 21 Fernández-Ruiz M, Silva JT, San-Juan R , et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 91 (5) 261-273
    CrossrefPubMedGoogle Scholar
  • 22 Solé A, Morant P, Salavert M, Pemán J, Morales P. Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11 (5) 359-365
    CrossrefPubMedGoogle Scholar
  • 23 Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61 (6) 915-919
    CrossrefPubMedGoogle Scholar
  • 24 Raviv Y, Kramer MR, Amital A, Rubinovitch B, Bishara J, Shitrit D. Outbreak of aspergillosis infections among lung transplant recipients. Transpl Int 2007; 20 (2) 135-140
    PubMedGoogle Scholar
  • 25 Husni RN, Gordon SM, Longworth DL , et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26 (3) 753-755
    CrossrefPubMedGoogle Scholar
  • 26 Goldfarb NS, Avery RK, Goormastic M , et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71 (2) 242-246
    CrossrefPubMedGoogle Scholar
  • 27 Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78 (2) 123-138
    CrossrefPubMedGoogle Scholar
  • 28 Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001; 3 (3) 161-167
    CrossrefPubMedGoogle Scholar
  • 29 De Pauw B, Walsh TJ, Donnelly JP , et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12) 1813-1821
    CrossrefPubMedGoogle Scholar
  • 30 Husain S, Mooney ML, Danziger-Isakov L , et al; ISHLT Infectious Diseases Council Working Group on Definitions. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant 2011; 30 (4) 361-374
    CrossrefPubMedGoogle Scholar
  • 31 Qin J, Meng X, Fang Y , et al. Computed tomography and clinical features of invasive pulmonary aspergillosis in liver transplant recipients. J Thorac Imaging 2012; 27 (2) 107-112
    CrossrefPubMedGoogle Scholar
  • 32 Park SY, Kim SH, Choi SH , et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis 2010; 12 (4) 309-315
    CrossrefPubMedGoogle Scholar
  • 33 Xu SC, Qiu LH, Liu WY, Feng YL. Initial computed tomography findings of invasive pulmonary aspergillosis in non-hematological patients. Chin Med J (Engl) 2012; 125 (17) 2979-2985
    PubMedGoogle Scholar
  • 34 Reichenberger F, Habicht J, Matt P , et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant 1999; 24 (11) 1195-1199
    CrossrefPubMedGoogle Scholar
  • 35 Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42 (10) 1417-1427
    CrossrefPubMedGoogle Scholar
  • 36 Park SH, Choi SM, Lee DG , et al. Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. Mycoses 2011; 54 (6) 523-530
    CrossrefPubMedGoogle Scholar
  • 37 Ulusakarya A, Chachaty E, Vantelon JM , et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000; 1 (2) 111-116
    CrossrefPubMedGoogle Scholar
  • 38 Husain S, Clancy CJ, Nguyen MH , et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 2008; 15 (12) 1760-1763
    CrossrefPubMedGoogle Scholar
  • 39 Pasqualotto AC, Xavier MO, Sánchez LB , et al. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. Transplantation 2010; 90 (3) 306-311
    PubMedGoogle Scholar
  • 40 Luong ML, Clancy CJ, Vadnerkar A , et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52 (10) 1218-1226
    CrossrefPubMedGoogle Scholar
  • 41 Boonsarngsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K. False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand J Infect Dis 2010; 42 (6-7) 461-468
    CrossrefPubMedGoogle Scholar
  • 42 Mikulska M, Furfaro E, Del Bono V , et al. Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 2012; 67 (7) 1746-1748
    CrossrefPubMedGoogle Scholar
  • 43 Gerlinger MP, Rousselot P, Rigaudeau S , et al. False positive galactomannan Platelia due to piperacillin-tazobactam. Med Mal Infect 2012; 42 (1) 10-14
    CrossrefPubMedGoogle Scholar
  • 44 Xavier MO, Pasqualotto AC, Aquino VR, Sukiennik TC, Severo LC. Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market. Braz J Infect Dis 2009; 13 (5) 353-355
    CrossrefPubMedGoogle Scholar
  • 45 Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3)beta-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010; 48 (11) 4083-4088
    CrossrefPubMedGoogle Scholar
  • 46 Ostrosky-Zeichner L, Alexander BD, Kett DH , et al. Multicenter clinical evaluation of the (1—>3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41 (5) 654-659
    CrossrefPubMedGoogle Scholar
  • 47 Herbrecht R, Denning DW, Patterson TF , et al; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6) 408-415
    CrossrefPubMedGoogle Scholar
  • 48 Walsh TJ, Anaissie EJ, Denning DW , et al; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (3) 327-360
    CrossrefPubMedGoogle Scholar
  • 49 Hiemenz JW, Raad II, Maertens JA , et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 2010; 29 (11) 1387-1394
    CrossrefPubMedGoogle Scholar
  • 50 Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?. Cancer 2010; 116 (22) 5290-5296
    CrossrefPubMedGoogle Scholar
  • 51 Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses 2013; May; 56 (3) 304-310
    CrossrefPubMedGoogle Scholar
  • 52 Singh N, Limaye AP, Forrest G , et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81 (3) 320-326
    CrossrefPubMedGoogle Scholar
  • 53 Wu N, Huang Y, Li Q, Bai C, Huang HD, Yao XP. Isolated invasive Aspergillus tracheobronchitis: a clinical study of 19 cases. Clin Microbiol Infect 2010; 16 (6) 689-695
    CrossrefPubMedGoogle Scholar
  • 54 Reichenspurner H, Gamberg P, Nitschke M , et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29 (1-2) 627-628
    CrossrefPubMedGoogle Scholar
  • 55 Minari A, Husni R, Avery RK , et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4 (4) 195-200
    CrossrefPubMedGoogle Scholar
  • 56 Mattner F, Chaberny IF, Weissbrodt H , et al. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole [Article in German]. Mycoses 2005; 48 (Suppl. 01) 51-55
    CrossrefPubMedGoogle Scholar
  • 57 Koo S, Kubiak DW, Issa NC , et al. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation 2012; 94 (3) 281-286
    PubMedGoogle Scholar
  • 58 Drew RH, Dodds Ashley E, Benjamin Jr DK, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77 (2) 232-237
    CrossrefPubMedGoogle Scholar
  • 59 Cadena J, Levine DJ, Angel LF , et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9 (9) 2085-2091
    CrossrefPubMedGoogle Scholar
  • 60 Monforte V, Ussetti P, Gavaldà J , et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010; 29 (5) 523-530
    CrossrefPubMedGoogle Scholar
  • 61 Neoh CF, Snell GI, Kotsimbos T , et al. Antifungal prophylaxis in lung transplantation—a world-wide survey. Am J Transplant 2011; 11 (2) 361-366
    CrossrefPubMedGoogle Scholar
  • 62 Corcoran TE, Venkataramanan R, Mihelc KM , et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006; 6 (11) 2765-2773
    CrossrefPubMedGoogle Scholar
  • 63 Luong ML, Hosseini-Moghaddam SM, Singer LG , et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant 2012; 12 (7) 1929-1935
    CrossrefPubMedGoogle Scholar
  • 64 Vadnerkar A, Nguyen MH, Mitsani D , et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29 (11) 1240-1244
    CrossrefPubMedGoogle Scholar
  • 65 Zwald FO, Spratt M, Lemos BD , et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38 (8) 1369-1374
    CrossrefPubMedGoogle Scholar
  • 66 Singer JP, Boker A, Metchnikoff C , et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31 (7) 694-699
    CrossrefPubMedGoogle Scholar
  • 67 Feist A, Lee R, Osborne S, Lane J, Yung G. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant 2012; 31 (11) 1177-1181
    CrossrefPubMedGoogle Scholar
  • 68 Chen L, Mulligan ME. Medication-induced periostitis in lung transplant patients: periostitis deformans revisited. Skeletal Radiol 2011; 40 (2) 143-148
    CrossrefPubMedGoogle Scholar
  • 69 Lustenberger DP, Granata JD, Scharschmidt TJ. Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient. Orthopedics 2011; 34 (11) e793-e796
    PubMedGoogle Scholar
  • 70 Mitsani D, Nguyen MH, Shields RK , et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012; 56 (5) 2371-2377
    CrossrefPubMedGoogle Scholar
  • 71 Gilgado F, Cano J, Gené J, Sutton DA, Guarro J. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol 2008; 46 (2) 766-771
    CrossrefPubMedGoogle Scholar
  • 72 Katragkou A, Dotis J, Kotsiou M, Tamiolaki M, Roilides E. Scedosporium apiospermum infection after near-drowning. Mycoses 2007; 50 (5) 412-421
    CrossrefPubMedGoogle Scholar
  • 73 Cortez KJ, Roilides E, Quiroz-Telles F , et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21 (1) 157-197
    CrossrefPubMedGoogle Scholar
  • 74 Musk M, Chambers D, Chin W, Murray R, Gabbay E. Successful treatment of disseminated scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant 2006; 25 (10) 1268-1272
    CrossrefPubMedGoogle Scholar
  • 75 Castiglioni B, Sutton DA, Rinaldi MG, Fung J, Kusne S. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 2002; 81 (5) 333-348
    CrossrefPubMedGoogle Scholar
  • 76 Sahi H, Avery RK, Minai OA , et al. Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant 2007; 26 (4) 350-356
    CrossrefPubMedGoogle Scholar
  • 77 Tamm M, Malouf M, Glanville A. Pulmonary scedosporium infection following lung transplantation. Transpl Infect Dis 2001; 3 (4) 189-194
    CrossrefPubMedGoogle Scholar
  • 78 Husain S, Muñoz P, Forrest G , et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40 (1) 89-99
    CrossrefPubMedGoogle Scholar
  • 79 Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007; 39 (1) 87-90
    CrossrefPubMedGoogle Scholar
  • 80 Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22 (2) 111-113
    PubMedGoogle Scholar
  • 81 Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20 (4) 695-704
    CrossrefPubMedGoogle Scholar
  • 82 Chang DC, Grant GB, O'Donnell K , et al; Fusarium Keratitis Investigation Team. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 2006; 296 (8) 953-963
    CrossrefPubMedGoogle Scholar
  • 83 Thomas PA, Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect 2013; 19 (3) 210-220
    CrossrefPubMedGoogle Scholar
  • 84 Dias N, Santos C, Portela M, Lima N. Toenail onychomycosis in a Portuguese geriatric population. Mycopathologia 2011; 172 (1) 55-61
    CrossrefPubMedGoogle Scholar
  • 85 Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA. Disseminated Fusarium infection originating from paronychia in a neutropenic patient: a case report and review of the literature. Cutis 2010; 85 (4) 191-194
    PubMedGoogle Scholar
  • 86 Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) 2011; 90 (1) 69-80
    CrossrefPubMedGoogle Scholar
  • 87 Guinvarc'h A, Guilbert L, Marmorat-Khuong A , et al. Disseminated Fusarium solani infection with endocarditis in a lung transplant recipient. Mycoses 1998; 41 (1-2) 59-61
    CrossrefPubMedGoogle Scholar
  • 88 Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001; 32 (8) 1237-1240
    CrossrefPubMedGoogle Scholar
  • 89 Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54 (Suppl. 01) S8-S15 DOI: 10.1093/cid/cir864.:S8-S15.
    CrossrefPubMedGoogle Scholar
  • 90 Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6 (10) 2365-2374
    CrossrefPubMedGoogle Scholar
  • 91 Singh N, Aguado JM, Bonatti H , et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200 (6) 1002-1011
    CrossrefPubMedGoogle Scholar
  • 92 Dannaoui E, Schwarz P, Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother 2009; 53 (8) 3549-3551
    CrossrefPubMedGoogle Scholar
  • 93 Sun HY, Aguado JM, Bonatti H , et al; Zygomycosis Transplant Study Group. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant 2009; 9 (9) 2166-2171
    CrossrefPubMedGoogle Scholar
  • 94 Mattner F, Weissbrodt H, Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis 2004; 36 (4) 312-314
    CrossrefPubMedGoogle Scholar
  • 95 Page AV, Evans AJ, Snell L, Liles WC. Primary cutaneous mucormycosis in a lung transplant recipient: case report and concise review of the literature. Transpl Infect Dis 2008; 10 (6) 419-425
    CrossrefPubMedGoogle Scholar
  • 96 McGuire FR, Grinnan DC, Robbins M. Mucormycosis of the bronchial anastomosis: a case of successful medical treatment and historic review. J Heart Lung Transplant 2007; 26 (8) 857-861
    CrossrefPubMedGoogle Scholar
  • 97 Pagano L, Offidani M, Fianchi L , et al; GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Infection Program. Mucormycosis in hematologic patients. Haematologica 2004; 89 (2) 207-214
    PubMedGoogle Scholar
  • 98 Cornely OA, Maertens J, Winston DJ , et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356 (4) 348-359
    CrossrefPubMedGoogle Scholar
  • 99 Ibrahim AS, Gebremariam T, Schwartz JA, Edwards Jr JE, Spellberg B. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009; 53 (2) 772-775
    CrossrefPubMedGoogle Scholar
  • 100 Ibrahim AS, Gebermariam T, Fu Y , et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117 (9) 2649-2657
    CrossrefPubMedGoogle Scholar
  • 101 Spellberg B, Ibrahim AS, Chin-Hong PV , et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67 (3) 715-722
    CrossrefPubMedGoogle Scholar